Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 5, 2008, Pages

  Sharma, Sunita ^a   Litonjua, Augusto A ^a   Tantisira, Kelan G ^a   Fuhlbrigge, Anne L ^a   Szefler, Stanley J ^b   Strunk, Robert C ^c   Zeiger, Robert S ^d   Murphy, Amy J ^a   Weiss, Scott T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Asthma; consistent bronchodilator response; outcomes

Indexed keywords

BUDESONIDE; NEDOCROMIL; PLACEBO; SALBUTAMOL;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

EID: 55649123882     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.09.004     Document Type: Article

References (24)

1. Masoli M., Fabian D., Holt S., and Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
2. Bousquet J., Clark T.J., Hurd S., Khaltaev N., Lenfant C., O'Byrne P., et al. GINA guidelines on asthma and beyond. Allergy 62 (2007) 102-112
3. Abramson M.J., Walters J., and Walters E.H. Adverse effects of beta-agonists: are they clinically relevant?. Am J Respir Med 2 (2003) 287-297
4. Postma Da D.V.K., Koeter G.H., and Sluiter H.J. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 134 (1986) 276-280
5. Tantisira K.G., Fuhlbrigge A.L., Tonascia J., Van Natta M., Zeiger R.S., Strunk R.C., et al. Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma. J Allergy Clin Immunol 117 (2006) 1264-1271
6. Beydon N., M'Buila C., Bados A., Peiffer C., Bernard A., Zaccaria I., et al. Interrupter resistance short-term repeatability and bronchodilator response in preschool children. Respir Med 101 (2007) 2482-2487
7. Tantisira K.G., and Weiss S.T. The pharmacogenetics of asthma: an update. Curr Opin Mol Ther 7 (2005) 209-217
8. Xu X., and Weiss S.T. Familial aggregation of bronchodilator response: a community-based study. Am J Respir Crit Care Med 166 (2002) 774
9. The Childhood Asthma Management Program Research Group. The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Control Clin Trials 20 (1999) 91-120
10. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343 (2000) 1054-1063
11. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005) 948-968
12. Eliasson O., and Degraff Jr. A.C. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis 132 (1985) 858-864
13. Dales R.E., Spitzer W.O., Tousignant P., Schechter M., and Suissa S. Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. Am Rev Respir Dis 138 (1988) 317-320
14. Kitch B.T., Paltiel A.D., Kuntz K.M., Dockery D.W., Schouten J.P., Weiss S.T., et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 126 (2004) 1875-1882
15. Martin R.J., Szefler S.J., King T.S., Kraft M., Boushey H.A., Chinchilli V.M., et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol 119 (2007) 73-80
16. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
17. O'Byrne P.M., and Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet 368 (2006) 794-803
18. Sorkness C.A., Lemanske Jr. R.F., Mauger D.T., Boehmer S.J., Chinchilli V.M., Martinez F.D., et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119 (2007) 64-72
19. Deykin A., Wechsler M.E., Boushey H.A., Chinchilli V.M., Kunselman S.J., Craig T.J., et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 175 (2007) 228-234
20. Zeiger R.S., Szefler S.J., Phillips B.R., Schatz M., Martinez F.D., Chinchilli V.M., et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117 (2006) 45-52
21. Drazen J.M., Silverman E.K., and Lee T.H. Heterogeneity of therapeutic responses in asthma. Br Med Bull 56 (2000) 1054-1070
22. Weiss St L.A., Lange C., Lazarus R., Liggett S.B., Bleeker E.R., and Tantisira K.G. Overview of the pharmacogenetics of asthma treatment. Pharmacogenom J 6 (2006) 311-326
23. Litonjua A.A., Silverman E.K., Tantisira K.G., Sparrow D., Sylvia J.S., and Weiss S.T. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest 126 (2004) 66-74
24. Raby B.A., and Weiss S.T. Beta2-adrenergic receptor genetics. Curr Opin Mol Ther 3 (2001) 554-566